Anatara Lifesciences Ltd · ASX:ANR
Anatara Lifesciences — Monsoon Communications Twilight Investor Briefing (August 2019)
27 slides from Anatara Lifesciences's conference presentation, Aug 23, 2019
Slide 1: ASX Release: Anatara Investor Presentation
ASX Release Anatara Investor Presentation For personal use only BRISBANE & MELBOURNE, 23rd August 2019: Anatara Lifesciences (ASX:ANR) is pleased to release to investors a copy of the presentation that Chief Executive Officer, Mr Steven Lydeamore, presented at the Monsoon Communications Twilight Inv
Slide 2: Twilight Investor Briefing August 2019
Twilight Investor Briefing August 2019 For personal use only Advancing gastrointestinal health
Slide 3: Disclaimer
2 Disclaimer For personal use only The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anatara Lifesciences Ltd, AC
Slide 4: Key Investor Message
3 Key Investor Message For personal use only More than ever, the world is looking for safe and effective solutions to gut health. The Anatara team is focussed on delivering evidence-based, commercially attractive solutions for gastrointestinal diseases in animals and humans.
Slide 5: Corporate Fast Facts
4 Corporate Fast Facts Board of Directors: For personal use only Sue MacLeman ASX ticker code Dr Jane Ryan ANR Dr Tracie Ramsdale Dr David Brookes Management: Steve Lydeamore, CEO Dr Tracey Brown, CSO Share Price Market Capitalisation Dr Michael West, COO $0.24* $11.86 million* Product Development A
Slide 6: Investment highlights: multiple shots on goal
5 Investment highlights: multiple shots on goal For personal use only Human health asset, GaRP: • Aimed at restoring and maintaining gut health with excellent (pre-clinical) data to date • Animal study results and human clinical study initiation anticipated late 2019 • Targeting partnering discussio
Slide 7: Need to combat antimicrobial resistance
6 Need to combat antimicrobial resistance For personal use only “Antimicrobial resistance is one of the most urgent health risks of our time and threatens to undo a century of medical progress.”’ Dr Tedros Ghebreyesus, Director-General, World Health Organisation (WHO) 2019 70% of bacteria globally h
Slide 8: Detach can help
7 Detach ® can help For personal use only Detach® increases survivability and provides health benefits to pre-weaning piglets • 15-20%5 of piglets born will die before weaning due to health issues including scour • Orally administered, non-antibiotic product for the control of scour in piglets • Nat
Slide 9: Detach Next Steps
8 Detach® Next Steps For personal use only • Secure international animal health partner(s) – 6-12 month timeframe – regulatory approval of Detach® in key overseas markets • opportunity to fast track registration in SE Asia – develop new formulations and administration methods for Detach® to expand u
Slide 10: From animals to humans
For personal use only From animals to humans
Slide 11: No guts, no glory: why microbiome is so hot right now!
10 No guts, no glory: why microbiome is so hot right now! For personal use only 6 6a Nature7 says A huge market According to Nature, $1.7 billion The global market for human has been spent on microbiome microbiome-based drugs and research in the last 10 years diagnostics should reach a market size o
Slide 12: Our place in the microbiome treatment landscape
11 Our place in the microbiome treatment landscape For personal use only Identifying a specific bacterial Drugs that specifically target the Fecal microbiota treatment (FMT) strain, or group of strains, that is bacteria that cause disease while delivered alive to the patient’s leaving the rest of th
Slide 13: Burgeoning microbiome market: our first targets
12 Burgeoning microbiome market: our first targets For personal use only Source: http://big.assets.huffingtonpost.com/2015_GutBacteriaA.png
Slide 14: IBS is the most commonly diagnosed gastrointestinal condition
13 For personal use only IBS is the most commonly diagnosed gastrointestinal condition and a significant cost burden on health care8 8 IBS Global Impact Report 2018 - https://badgut.org/wp-content/uploads/IBS-Global-Impact-Report.pdf
Slide 15: IBS in a minute
14 IBS in a minute 11% For personal use only IBS affects around 11% of the global population9 It costs around $21billion Patients have a poor quality of or more annually in direct medical life and use healthcare system costs and absenteeism10 more than other patients IBS is a functional disorder, re
Slide 16: Profound impact on patients
15 Profound impact on patients For personal use only “Imagine a day where you fell ill from having eaten too much, then imagine that day lasts months at a time.” Australian IBS patient12 12 IBS Global Impact Report 2018 https://badgut.org/wp-content/uploads/IBS-Global-Impact-Report.pdf
Slide 17: IBS - one of the most burdensome chronic ailments
16 IBS - one of the most burdensome chronic ailments reported by patients13 For personal use only Individuals with IBS restrict their activities an average of 45% of IBS-D* patients agreed with the statement 73 DAYS a year 13 “I’m willing to try anything to help manage my IBS”14 Patients reported th
Slide 18: USA gastrointestinal health market
17 USA gastrointestinal health market For personal use only US $8b USA digestive remedies and GI supplement sales 8/10 US$5b Adults suffer annually OTC** digestive remedies 2018 15 from a digestive issue15 US$3b ↑ 11.9% GI* supplement sales 201816 OTC** digestive remedies over the past 5 years15 * G
Slide 19: Global consumer health market opportunity
18 Global consumer health market opportunity For personal use only US $5.7b Global probiotic supplement sales 17 Probiotic supplements Other GI supplements OTC digestive supplements Align® (P&G) sales Iberogast® (Bayer) sales Buscopan® (Sanofi) sales (U.S.) 2018: (Germany) 2018: (Global) 2018: US$17
Slide 20: Primary underlying factors of IBS and IBD
19 3 primary underlying factors of IBS and IBD For personal use only
Slide 21: How are these addressed?
20 How are these addressed? Dietary modification For personal use only Probiotics – limited evidence for clinical efficacy Anti-inflammatory drugs – severe GaRP side effect profile No direct treatments with long term results *Gastrointestinal ReProgramming (GaRP) dietary supplement
Slide 22: Changing the game for IBS
21 Changing the game for IBS For personal use only GaRP dietary supplement • Regenerative, multi-component dietary supplement • Dual targeted formulation (small intestine and colon) • Positioned as either an adjunct to existing therapies, or a sole therapy for IBS • Designed to address 3 primary und
Slide 23: Assumption or fact?
22 Assumption or fact? For personal use only Anatara’s Approach: evidence-based complementary medicine • Most complementary medicines are listed, not registered medicines • No requirement for own safety or efficacy studies for listed medicines • Anatara’s approach is to develop its own evidence for
Slide 24: Grounded in scientific evidence
23 Grounded in scientific evidence For personal use only Successful Proof of Concept Studies (February 2019) Demonstrated using industry-standard in vitro gut models
Slide 25: Next steps: human trial
24 Next steps: human trial For personal use only • Pre-clinical animal studies are currently underway where GaRP is being evaluated in a model representative of IBD – Data expected Q4 2019 • Pre-trial activities for a human clinical study in IBS patients have commenced, with a view to study initiati
Slide 26: Bringing science to supplements
25 Bringing science to supplements • Evidence-based breakthrough product for IBS and IBD For personal use only – Triple-targeted therapeutic approach • anti-adhesion; anti-inflammatory; mucosal regeneration – Components delivered to where they can be most effective 19 • Fewer or lower regulatory req
Slide 27: Contact Anatara Lifesciences Ltd
26 For personal use only Contact Anatara Lifesciences Ltd Steven Lydeamore, CEO +61 438 027 172 slydeamore@anatara.com www.anataralifesciences.com @AnataraANR anatara-lifesciences-ltd
Anatara Lifesciences — Monsoon Communications Twilight Investor Briefing (August 2019) on 6ix